Axoft Receives FDA Breakthrough Device Designation for Soft Neural Implant
Summary
Axoft announced that the FDA granted Breakthrough Device Designation for its soft neural implant technology. The company's implants are made from ultra-soft materials designed to match the mechanical properties of brain tissue, potentially reducing the foreign body response that can degrade signal quality over time. The initial indication targets paralysis and communication restoration.
Why it matters
The foreign body response to traditional rigid neural implants is a major challenge limiting long-term BCI performance. Axoft's ultra-soft materials approach could potentially enable stable neural recording over much longer periods, addressing one of the most significant technical barriers to chronic BCI use. Breakthrough Device Designation provides an expedited regulatory pathway for this promising technology.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial